watermark logo

5 Views· 17 August 2022

Rapid viral evolution


wendiffr568576
Subscribers

BA.5, immune escape

Vaccines and previous infections are protective against severe disease

Percentages of positives that were infected more than 90 days ago

Progressively increasing

Now, 12 % reinfections

3 months ago, 8% reinfections

6 months ago, 5% reinfections

https://www.youtube.com/watch?v=TwQp3Yc82ak

R = 1.1

Up 27% on the week

UK, 1 in 21

Scotland 1 in 15, highest ever rates

Young people and young adults highest

Will go up for a time, summer mixing, festivals

Consistent with ONS data

https://www.ons.gov.uk/peoplep....opulationandcommunit

One week ahead

Hospital admissions up 37%

List of covid symptoms

Runny nose, 66%

Sore throat, 65%

Headache, 64%

Persistent cough, 63%

Fatigue, 62%

Sneezing, 53%

Hoarse, 44%

Joint pains, 35%

Fever, 31%

Chills or shivers, 30%

Muscle pains 29%

Dizzy, 27%

Brain fog, 24%

Sore eyes, 22%

Altered smell, 21%

Lower back pain, 22%

Swollen glands, 19%

Skipped meals, 17%

Chest pain, 15%

BA.5 is milder than previous variants

Still time off work

Hospital admissions due to large numbers

Official data UK

https://coronavirus.data.gov.uk

Coronavirus vaccines should be updated for fall

https://www.fda.gov/advisory-c....ommittees/advisory-c

FDA advisory committee


Deadline, vaccine formula for October, now

BA.1 vaccine, in human tests for months

Arnold Monto, FDA advisory committee

We’re being asked, more or less, to have a crystal ball today

New multi-strain vaccine, original and omicron

Some wanted BA.4 and BA.5, others BA.1

Moderna, Novavax, Pfizer, each presented data to support their strategy

Moderna, bivalent, for example, original version + BA.1 variant

Pfizer BioNTech, only BA.1

Pfizer presented mouse data on BA.4 and BA.5

Novavax’s vaccine (not yet authorized in United States), additional doses of its existing vaccine could be protective

? will these new formulations apply to children without testing

? local or global

Lyme disease

Show more


Up next


0 Comments